FZD7 and hepatocellular carcinoma: Additionally, a high level of cripto-1 sustained in either sorafenib-resistant HCC cells or patient-derived xenografts (PDXs) activates Wnt/β-catenin signaling by binding to FZD7/LRP6 and DVL3.